Skip to content
Open access

Continuous ambulatory ECG monitoring of up to 14 days increases detection of high-risk ventricular tachyarrhythmias compared with the first 48 hours in hypertrophic cardiomyopathy

Oct 2026 · European Heart Journal · Vol 47 · 0 citations

TL;DR

Extended ambulatory ECG monitoring of up to 14 days in patients with HCM significantly increases detection of NSVT and other actionable arrhythmias vs. short-term (≤48 h) monitoring and aligns with prior prospective studies and support extended monitoring for comprehensive arrhythmia assessment and SCD risk stratification in HCM.

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and a leading cause of sudden cardiac death (SCD). Nonsustained ventricular tachycardia (NSVT) identified on short-term (≤48 h) ambulatory ECG monitoring is associated with increased SCD risk. Prior prospective studies, including EXAMINE-HCM, demonstrated increased detection of NSVT with extended ambulatory cardiac monitoring (ACM) of up to 14 days, but real-world data are limited. To compare diagnostic yield of NSVT and other clinically significant arrhythmias during the first 48 h of monitoring vs. the full monitoring period of up to 14 days in patients with HCM. We retrospectively analyzed U.S. patients ≥18 y with HCM who underwent continuous patch-based ACM for up to 14 days from 2018-2022. Commercial fee-for-service and Medicare Advantage claims data were linked to a clinical data warehouse containing the continuous ACM results. From this linked cohort, we identified patients with HCM (ICD-10 I42.1/I42.2) who underwent 3-14 days of continuous patch-based ACM and compared arrhythmia detection during the first 48 h of monitoring to the full monitoring period (of up to 14 days). Outcomes included detection of any NSVT, high-risk NSVT (≥8 beats, >200bpm, or ≥2 runs within any 48-hour period), and other clinically actionable arrhythmias (AF, SVT, pause, AV block). Among 5,325 patients with HCM (median age 65 y; 50% female), median ACM wear time was 13.2 (IQR 6.9) days with 98.9% (IQR 3.5%) analyzable time. Any NSVT was detected in 1,184 (22%) and high-risk NSVT in 651 (12%) patients. Of those with NSVT, 60% had detection only after the first 48 h of monitoring (p<0.001 vs. ≤48 h monitoring). For high-risk VT, 48% had detection only after 48 h of monitoring (p<0.001 vs. ≤48 h monitoring). Clinically actionable arrhythmias were detected in 1,923 (36%) patients, with 681 (35%) detected only after the first 48 h, including 128 (20%) with AF ≥30 seconds. Extended ambulatory ECG monitoring of up to 14 days in patients with HCM significantly increases detection of NSVT and other actionable arrhythmias vs. short-term (≤48 h) monitoring. These real-world findings align with prior prospective studies and support extended monitoring for comprehensive arrhythmia assessment and SCD risk stratification in HCM.HCM-abstract-table

Read PDF

Similar papers

Review Open access Oct 2026

Detection of arrhythmias by 24-hour holter monitoring versus 14-day continuous electrocardiogram patch: a systematic review and meta-analysis

Twenty-four-hour ambulatory Holter monitoring has long been considered the gold standard for cardiac arrhythmia diagnosis. However, its limited monitoring window frequently restricts the detection of paroxysmal, intermittent, or infrequent arrhythmic events with significant prognostic and therapeutic implications...

J. F. De Sousa, F. Kelly, L. Dalponte et al. · 0 citations
Open access Oct 2026

Echocardiographic risk stratification for atrial fibrillation detection using 7-day holter monitoring in patients without history of atrial fibrillation: a prospective study

A novel echocardiographic risk score provides effective risk stratification for subclinical AF and establishes a robust framework for personalized triage by prioritizing 7-day Holter monitoring for high-risk patients to maximize diagnostic yield.

P. Somboonlakkana, S. Leelasithorn, O. See et al. · 0 citations
Open access Oct 2026

Detection of clinically significant atrial fibrillation in patients with ahre: diagnostic value of long-term wearable ECG monitoring

Atrial high-rate episodes (AHREs) represent a subclinical phenotype of atrial tachyarrhythmias and may precede atrial fibrillation (AF). Brief episodes (<30 s) detected during standard 24-hour Holter monitoring have uncertain prognostic value and may remain underestimated. Prolonged wearable ECG monitoring may im...

T. Danilevich, L. Rasputina · 0 citations
Open access Oct 2026

Hourly premature atrial contractions in 24-h holter ECG monitoring of acute ischemic stroke patients: insights from the FIND-AF 2 trial

An increased number of premature atrial contractions (PACs) has been associated with an increased risk of atrial fibrillation (AF) and ischemic stroke. Prior studies used 24-hours or 48-hours of ECG monitoring and thresholds of ≥720 PACs/24 hours to define excessive supraventricular ectopy (ESVEA). To dete...

E. Richter, S. Beimel, K. Wasser et al. · 0 citations
Open access Oct 2026

Incidence and burden of new-onset atrial fibrillation after STEMI detected by 14-day ECG patch monitoring

Reported new-onset atrial fibrillation (NOAF) incidence following ST-segment elevation myocardial infarction (STEMI) varies widely, likely reflecting disease severity and differences in monitoring intensity. Robust data on post-STEMI AF burden is needed to guide therapeutic decisions, such as initiation of antico...

C. Moser, A. Bettelini, J. Bruegger et al. · 0 citations
Open access Oct 2026

Peak high-sensitivity troponin-T concentration and risk of heart failure in patients with suspected acute coronary syndrome

Acute coronary syndrome (ACS) is one of the most frequent causes of heart failure. In patients presenting with suspected ACS, it is currently unknown whether peak high-sensitivity troponin-T (hsTnT) is correlated with the short- and long-term risks of subsequent heart failure. To examine the short- and lon...

P. Ahle Erichsen, M. Afzal, J. Frary et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.